Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Mark Breidenbach maintains an Outperform rating on Nurix Therapeutics (NASDAQ:NRIX) and raises the price target from $25 to $27.
August 14, 2024 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has maintained its Outperform rating on Nurix Therapeutics and increased the price target from $25 to $27.
The increase in price target from $25 to $27 by a reputable analyst firm like Oppenheimer is a positive signal for investors, indicating confidence in the company's future performance. This is likely to have a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100